MX2012008638A - Metodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4. - Google Patents
Metodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4.Info
- Publication number
- MX2012008638A MX2012008638A MX2012008638A MX2012008638A MX2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A
- Authority
- MX
- Mexico
- Prior art keywords
- dll4
- antagonists
- block
- antibodies
- dll4 antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención provee métodos para prevenir, tratar o mitigar diabetes al administrar a un sujeto que necesita el mismo una cantidad terapéuticamente efectiva de antagonistas de D114 que bloquean las vías de señal de D114 - Notch. Como se observa en un modelo de diabetes en ratón, los antagonistas de D114 presentan efectos protectores sobre islotes pancreáticos, reducen los niveles de glucosa en la sangre, y bloquean la producción de auto-anticuerpos, incluyendo aquellos contra insulina y ácido glutámico descarboxilasa 65 (GAD65), mediante la expansión de células T reguladoras (Tregs). Por lo tanto, la presente invención además provee métodos para reducir los niveles de glucosa en la sangre, y/o reducir o bloquear la producción de auto-anticuerpos, al administrar a un sujeto que necesita el mismo una cantidad terapéuticamente efectiva de antagonistas de D114. Los antagonistas de D114 adecuados para la invención incluyen anticuerpos o fragmentos de anticuerpo que se unen específicamente a D114 y bloquean las interacciones D114 - Notch, el dominio extracelular de D114, y similares.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29980110P | 2010-01-29 | 2010-01-29 | |
| US36168710P | 2010-07-06 | 2010-07-06 | |
| US38869710P | 2010-10-01 | 2010-10-01 | |
| PCT/US2011/022817 WO2011094467A2 (en) | 2010-01-29 | 2011-01-28 | Methods of treating diabetes with dll4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008638A true MX2012008638A (es) | 2012-12-05 |
| MX343555B MX343555B (es) | 2016-11-10 |
Family
ID=43925413
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008740A MX343553B (es) | 2010-01-29 | 2011-01-28 | Métodos de tratamiento de enfermedades autoinmunes con antagonistas de ligando tipo delta 4. |
| MX2012008638A MX343555B (es) | 2010-01-29 | 2011-01-28 | Métodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008740A MX343553B (es) | 2010-01-29 | 2011-01-28 | Métodos de tratamiento de enfermedades autoinmunes con antagonistas de ligando tipo delta 4. |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8765125B2 (es) |
| EP (2) | EP2528945B1 (es) |
| JP (2) | JP5997613B2 (es) |
| KR (2) | KR101797918B1 (es) |
| CN (2) | CN102947336B (es) |
| AR (1) | AR080026A1 (es) |
| AU (2) | AU2011210771B2 (es) |
| BR (2) | BR112012018820A8 (es) |
| CA (2) | CA2787394C (es) |
| CY (2) | CY1118223T1 (es) |
| DK (2) | DK2528945T3 (es) |
| ES (2) | ES2609663T3 (es) |
| HR (2) | HRP20170249T1 (es) |
| HU (2) | HUE031432T2 (es) |
| IL (2) | IL220887A (es) |
| JO (2) | JO3183B1 (es) |
| LT (2) | LT2528945T (es) |
| MX (2) | MX343553B (es) |
| MY (2) | MY156538A (es) |
| PL (2) | PL2528945T3 (es) |
| PT (2) | PT2528945T (es) |
| RS (2) | RS55715B1 (es) |
| RU (2) | RU2587624C2 (es) |
| SG (4) | SG182528A1 (es) |
| SI (2) | SI2528946T1 (es) |
| SM (3) | SMT201600412B (es) |
| TW (2) | TWI600433B (es) |
| UY (1) | UY33206A (es) |
| WO (2) | WO2011094465A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| UA112743C2 (uk) | 2010-03-02 | 2016-10-25 | Еббві Інк. | Терапевтичний dll4-зв'язувальний білок |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| MY194330A (en) | 2012-11-01 | 2022-11-28 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof |
| TW201438736A (zh) * | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以ｄｌｌ４拮抗劑治療卵巢癌之方法 |
| US10184010B2 (en) | 2013-07-09 | 2019-01-22 | Ablbio | Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof |
| JP6560200B2 (ja) * | 2013-10-17 | 2019-08-14 | ザ ジェネラル ホスピタル コーポレイション | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| WO2015154795A1 (en) * | 2014-04-08 | 2015-10-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Combination therapy for the treatment of autoimmune diseases |
| EP3212233B1 (en) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| US11446262B2 (en) | 2018-11-29 | 2022-09-20 | Debora Zucco Sassi Yonezawa Siviglia | Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination |
| EP3886856A4 (en) * | 2018-11-29 | 2022-01-19 | Zucco Sassi Yonezawa Siviglia, Debora | METHOD FOR TREATING OR PREVENTING SEIZURES ASSOCIATED WITH AN EPILEPTIC DISORDER |
| JPWO2022210802A1 (es) * | 2021-03-30 | 2022-10-06 | ||
| WO2023159166A1 (en) * | 2022-02-18 | 2023-08-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use |
| WO2025212726A2 (en) | 2024-04-04 | 2025-10-09 | Compass Therapeutics, Inc. | Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| EP1505977B1 (en) * | 2002-05-21 | 2014-09-10 | Gilead Sciences, Inc. | Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| DK1962895T3 (da) | 2005-12-16 | 2013-03-04 | Regeneron Pharma | TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST |
| HRP20120175T1 (hr) | 2006-06-02 | 2012-03-31 | Regeneron Pharmaceuticals | Antitijela s visokim afinitetom za humani il-6 receptor |
| MX2008015541A (es) * | 2006-06-06 | 2008-12-18 | Genentech Inc | Anticuerpos anti-dll4 y metodos que los usan. |
| US20080014196A1 (en) | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| JP5529536B2 (ja) * | 2006-08-07 | 2014-06-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 虚血性障害又は血管不全の治療におけるＤｌｌ４アンタゴニストの使用 |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
-
2011
- 2011-01-23 JO JOP/2011/0021A patent/JO3183B1/ar active
- 2011-01-26 AR ARP110100250A patent/AR080026A1/es unknown
- 2011-01-28 MX MX2012008740A patent/MX343553B/es active IP Right Grant
- 2011-01-28 HU HUE11701933A patent/HUE031432T2/en unknown
- 2011-01-28 JP JP2012551293A patent/JP5997613B2/ja active Active
- 2011-01-28 AU AU2011210771A patent/AU2011210771B2/en active Active
- 2011-01-28 SM SM201600412T patent/SMT201600412B/it unknown
- 2011-01-28 CA CA2787394A patent/CA2787394C/en active Active
- 2011-01-28 RS RS20170142A patent/RS55715B1/sr unknown
- 2011-01-28 RS RS20170036A patent/RS55595B1/sr unknown
- 2011-01-28 TW TW105101963A patent/TWI600433B/zh not_active IP Right Cessation
- 2011-01-28 BR BR112012018820A patent/BR112012018820A8/pt not_active Application Discontinuation
- 2011-01-28 EP EP11701735.0A patent/EP2528945B1/en active Active
- 2011-01-28 HR HRP20170249TT patent/HRP20170249T1/hr unknown
- 2011-01-28 ES ES11701933.1T patent/ES2609663T3/es active Active
- 2011-01-28 LT LTEP11701735.0T patent/LT2528945T/lt unknown
- 2011-01-28 PT PT117017350T patent/PT2528945T/pt unknown
- 2011-01-28 PL PL11701735T patent/PL2528945T3/pl unknown
- 2011-01-28 TW TW100103219A patent/TWI564019B/zh not_active IP Right Cessation
- 2011-01-28 MY MYPI2012003169A patent/MY156538A/en unknown
- 2011-01-28 US US13/015,637 patent/US8765125B2/en active Active
- 2011-01-28 SG SG2012052056A patent/SG182528A1/en unknown
- 2011-01-28 KR KR1020127022496A patent/KR101797918B1/ko not_active Expired - Fee Related
- 2011-01-28 ES ES11701735.0T patent/ES2605430T3/es active Active
- 2011-01-28 KR KR1020127022506A patent/KR101832118B1/ko not_active Expired - Fee Related
- 2011-01-28 US US13/015,652 patent/US8889133B2/en active Active
- 2011-01-28 UY UY0001033206A patent/UY33206A/es not_active Application Discontinuation
- 2011-01-28 RU RU2012136817/10A patent/RU2587624C2/ru not_active IP Right Cessation
- 2011-01-28 WO PCT/US2011/022810 patent/WO2011094465A1/en not_active Ceased
- 2011-01-28 SI SI201131020A patent/SI2528946T1/sl unknown
- 2011-01-28 BR BR112012018766A patent/BR112012018766A2/pt active Search and Examination
- 2011-01-28 SI SI201131011A patent/SI2528945T1/sl unknown
- 2011-01-28 SM SM20170021T patent/SMT201700021T1/it unknown
- 2011-01-28 SG SG10201500416RA patent/SG10201500416RA/en unknown
- 2011-01-28 HR HRP20170130TT patent/HRP20170130T1/hr unknown
- 2011-01-28 CN CN201180016820.4A patent/CN102947336B/zh not_active Expired - Fee Related
- 2011-01-28 RU RU2012136816/10A patent/RU2587620C2/ru not_active IP Right Cessation
- 2011-01-28 WO PCT/US2011/022817 patent/WO2011094467A2/en not_active Ceased
- 2011-01-28 SG SG10201500404QA patent/SG10201500404QA/en unknown
- 2011-01-28 HU HUE11701735A patent/HUE032985T2/en unknown
- 2011-01-28 PL PL11701933T patent/PL2528946T3/pl unknown
- 2011-01-28 SG SG2012052049A patent/SG182527A1/en unknown
- 2011-01-28 CN CN2011800165511A patent/CN102884081A/zh active Pending
- 2011-01-28 DK DK11701735.0T patent/DK2528945T3/en active
- 2011-01-28 LT LTEP11701933.1T patent/LT2528946T/lt unknown
- 2011-01-28 MY MYPI2012003168A patent/MY156353A/en unknown
- 2011-01-28 EP EP11701933.1A patent/EP2528946B1/en active Active
- 2011-01-28 JP JP2012551294A patent/JP5883801B2/ja active Active
- 2011-01-28 PT PT117019331T patent/PT2528946T/pt unknown
- 2011-01-28 MX MX2012008638A patent/MX343555B/es active IP Right Grant
- 2011-01-28 CA CA2787615A patent/CA2787615C/en active Active
- 2011-01-28 DK DK11701933.1T patent/DK2528946T3/en active
- 2011-01-28 AU AU2011210773A patent/AU2011210773B2/en active Active
-
2012
- 2012-07-11 IL IL220887A patent/IL220887A/en not_active IP Right Cessation
- 2012-07-11 IL IL220889A patent/IL220889A/en not_active IP Right Cessation
-
2014
- 2014-05-22 US US14/285,409 patent/US20140255429A1/en not_active Abandoned
-
2016
- 2016-11-14 CY CY20161101167T patent/CY1118223T1/el unknown
-
2017
- 2017-01-04 CY CY20171100010T patent/CY1118551T1/el unknown
- 2017-01-16 SM SM201700021T patent/SMT201700021B/it unknown
- 2017-03-19 JO JOP/2017/0065A patent/JO3242B1/ar active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX343555B (es) | Métodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4. | |
| AU2018253580A1 (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| AU2011270668A8 (en) | CNS delivery of therapeutic agents | |
| MX354776B (es) | Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal. | |
| NZ620326A (en) | Cd37 immunotherapeutic combination therapies and uses thereof | |
| TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| WO2013033657A3 (en) | CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY | |
| WO2014004993A3 (en) | Methods of reducing ldl-p | |
| PH12014502217A1 (en) | Methods for improving diaphragm function | |
| MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| GB2496799A (en) | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders | |
| MX2014002967A (es) | Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas. | |
| WO2011140208A3 (en) | Methods and compositions for diagnosing and treating autoimmune disorders | |
| GB2477256A (en) | Medicament and method of diagnosis | |
| MX347372B (es) | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. | |
| MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
| WO2012068463A3 (en) | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) | |
| WO2010057647A3 (en) | Methods and compositions for the diagnosis and treatment of diabetes | |
| MX2015015519A (es) | Regulador de papalisina. | |
| EP2566502A4 (en) | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION | |
| MY154376A (en) | A transdermal fluid | |
| MX2014006990A (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| GB201101793D0 (en) | Weight related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |